Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Other Health

Biotechnology

General Health

Pharmaceutical

Health

Science

Oncology

Other Science

Ferring Pharmaceuticals

More Like This

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices